Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1975 1
1976 1
1983 2
1984 3
1985 1
1986 3
1987 4
1989 1
1990 6
1991 13
1992 4
1993 6
1994 12
1995 13
1996 16
1997 11
1998 25
1999 32
2000 25
2001 26
2002 42
2003 68
2004 83
2005 112
2006 105
2007 149
2008 136
2009 188
2010 176
2011 187
2012 217
2013 257
2014 271
2015 279
2016 285
2017 277
2018 269
2019 282
2020 282
2021 310
2022 255
2023 228
2024 236
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,273 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Knowler WC, et al. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512. N Engl J Med. 2002. PMID: 11832527 Free PMC article. Clinical Trial.
The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin
The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respecti …
Metformin: Is it a drug for all reasons and diseases?
Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, MacDonald R, Hollenberg MD, Hill MA. Triggle CR, et al. Metabolism. 2022 Aug;133:155223. doi: 10.1016/j.metabol.2022.155223. Epub 2022 May 29. Metabolism. 2022. PMID: 35640743 Free article. Review.
The objectives for this review are to: 1) evaluate the putative mechanism(s) of action of metformin; 2) analyze the controversial evidence for metformin's effectiveness in the treatment of diseases other than type 2 diabetes; 3) assess the reproducibility of …
The objectives for this review are to: 1) evaluate the putative mechanism(s) of action of metformin; 2) analyze the controversial evi …
Early Metformin in Gestational Diabetes: A Randomized Clinical Trial.
Dunne F, Newman C, Alvarez-Iglesias A, Ferguson J, Smyth A, Browne M, O'Shea P, Devane D, Gillespie P, Bogdanet D, Kgosidialwa O, Egan A, Finn Y, Gaffney G, Khattak A, O'Keeffe D, Liew A, O'Donnell M. Dunne F, et al. JAMA. 2023 Oct 24;330(16):1547-1556. doi: 10.1001/jama.2023.19869. JAMA. 2023. PMID: 37786390 Free PMC article. Clinical Trial.
OBJECTIVE: To test whether early initiation of metformin reduces insulin initiation or improves fasting hyperglycemia at gestation weeks 32 or 38. ...CONCLUSION AND RELEVANCE: Early treatment with metformin was not superior to placebo for the composite primary outco …
OBJECTIVE: To test whether early initiation of metformin reduces insulin initiation or improves fasting hyperglycemia at gestation we …
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis.
Coyle C, Cafferty FH, Vale C, Langley RE. Coyle C, et al. Ann Oncol. 2016 Dec;27(12):2184-2195. doi: 10.1093/annonc/mdw410. Epub 2016 Sep 28. Ann Oncol. 2016. PMID: 27681864 Free PMC article. Review.
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant therapy in individual cancer types has …
BACKGROUND: Metformin use has been associated with a reduced risk of developing cancer and an improvement in overall cancer survival …
Metformin versus insulin for the treatment of gestational diabetes.
Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Rowan JA, et al. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. N Engl J Med. 2008. PMID: 18463376 Free article. Clinical Trial.
RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. ...There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational …
RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supple …
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Campbell JM, Bellman SM, Stephenson MD, Lisy K. Campbell JM, et al. Ageing Res Rev. 2017 Nov;40:31-44. doi: 10.1016/j.arr.2017.08.003. Epub 2017 Aug 10. Ageing Res Rev. 2017. PMID: 28802803 Review.
Overall, 260 full-texts were reviewed and 53 met the inclusion criteria. Diabetics taking metformin had significantly lower all-cause mortality than non-diabetics (hazard ratio (HR)=0.93, 95%CI 0.88-0.99), as did diabetics taking metformin compared to diabetics rece …
Overall, 260 full-texts were reviewed and 53 met the inclusion criteria. Diabetics taking metformin had significantly lower all-cause …
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.
Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP; Diabetes Prevention Program Research Group. Aroda VR, et al. J Clin Endocrinol Metab. 2016 Apr;101(4):1754-61. doi: 10.1210/jc.2015-3754. Epub 2016 Feb 22. J Clin Endocrinol Metab. 2016. PMID: 26900641 Free PMC article. Clinical Trial.
Participants were assigned to the placebo group (PLA) (n = 1082) or the metformin group (MET) (n = 1073) for 3.2 years; subjects in the metformin group received open-label metformin for an additional 9 years. ...B12 levels were assessed at 5 years (n = 857, n …
Participants were assigned to the placebo group (PLA) (n = 1082) or the metformin group (MET) (n = 1073) for 3.2 years; subjects in t …
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Wu H, et al. Nat Med. 2017 Jul;23(7):850-858. doi: 10.1038/nm.4345. Epub 2017 May 22. Nat Med. 2017. PMID: 28530702 Clinical Trial.
Recent evidence implicates the gut microbiota as a site of metformin action. In a double-blind study, we randomized individuals with treatment-naive T2D to placebo or metformin for 4 months and showed that metformin had strong effects on the gut microbiome. . …
Recent evidence implicates the gut microbiota as a site of metformin action. In a double-blind study, we randomized individuals with …
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Garber AJ, et al. Am J Med. 1997 Dec;103(6):491-7. doi: 10.1016/s0002-9343(97)00254-4. Am J Med. 1997. PMID: 9428832 Free article. Clinical Trial.
After a 3-week, single-blind, placebo-controlled washout, 451 patients with fasting plasma glucose levels of at least 180 mg/dL were randomized to receive an 11-week course of placebo or metformin given at 500, 1000, 1500, 2000, or 2500 mg daily. RESULTS: Metformin
After a 3-week, single-blind, placebo-controlled washout, 451 patients with fasting plasma glucose levels of at least 180 mg/dL were randomi …
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Nazirudeen R, Sridhar S, Priyanka R, Sumathi B, Natarajan V, Subbiah E, Raghavan KS, Sangumani J. Nazirudeen R, et al. Clin Endocrinol (Oxf). 2023 Aug;99(2):198-205. doi: 10.1111/cen.14931. Epub 2023 Jun 2. Clin Endocrinol (Oxf). 2023. PMID: 37265016 Clinical Trial.
The objective is to compare the effect of metformin monotherapy versus a combination of metformin with Myoinositol and d-chiro-inositol in PCOS. ...CONCLUSIONS: The addition of myoinositol to metformin exerts additional benefits in improving menstrual cycle r …
The objective is to compare the effect of metformin monotherapy versus a combination of metformin with Myoinositol and d-chiro …
4,273 results